Dhaka, Nov. 26 -- The report that the government has finally given the much-awaited ethical permission for the clinical trial of the home-grown anti-COVID-19 vaccine, Bangavax, on humans, is at the same time heart warming and welcome. With this nod of approval from the Bangladesh Medical Research Council (BMRC) to go ahead with the trial, there is yet another step, the final permission from the Directorate General of Drug Administration (DGDA), before beginning the human trial. As the data from the trial on monkeys were reportedly found to be convincing by the BMRC, the DGDA's green signal should desirably be prompt. In fact, the wait for this phase of the trial has been rather long as the local research body, the Globe Biotech Ltd., firs...